Osteoporosis Breakthrough: 25AGAIN.Com Announces Harvard Study Proving Natural FDA Supplement Reverses Osteoporosis and Increases Bone Density
Posted on: Monday, 27 June 2005, 09:00 CDT
25AGAIN.com announces a major clinical study at Harvard University that reports bone mineral density "increased significantly" with no side effects. The 25AGAIN(TM) Pill is a natural FDA dietary supplement made from the Mexican wild yam.
Published in the Journal of Clinical Endocrinology and Metabolism, the study was conducted at Children's Hospital in Boston by Harvard's Dr. Catherine M. Gordon and colleagues on 61 patients with anorexia nervosa. The results showed that DHEA, the active ingredient in 25AGAIN(TM), not only slows the destruction of bone, but promotes its growth.
According to the National Osteoporosis Foundation, 44 million Americans, including 55% of all men and women over 50, have low bone density. Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. The most common fractures occur in the hip, spine, and wrist. Daily supplementation of 25AGAIN(TM) after age 40 can increase bone density and prevent osteoporosis.
About 25AGAIN.com
The 25AGAIN(TM) Anti-Aging Pill is a natural supplement that the body converts into 50 essential hormones, including testosterone and estrogen. These hormones peak at age 25, then decrease dramatically to 50% by age 40, and 20% by age 70, causing the symptoms of aging. Over 2,000 clinical studies (see RESEARCH page at www.25again.com) have proven that 25AGAIN's active ingredient DHEA burns fat, increases sex drive in men and women, relieves arthritis (Stanford study), reverses osteoporosis (Harvard study), relieves depression (Univ. of California study), renews energy, improves immunity, relieves PMS, renews skin tone and moisture, and improves memory.
For more information, contact Wayne Josephson at 952-465-4922 or visit www.25again.com.
Source: Business Wire
Related Articles
- Study Shows Aging Adults Avoid Exercise Because Of Health Worries
- Osta Receives Funding From Institute for the Study of Aging
- Cellgate Initiates Phase I Clinical Study in Age-Related Macular Degeneration
- Newsweek Hosts Special Capitol Hill Panel Discussion on 'The New Age of Cancer Clinical Trials: Issues and Opportunities'
- Institute for the Study of Aging and Elan Pharmaceuticals Announce Winners of New Alzheimer's Disease Drug Discovery Award Program
- Bone Biology and the Clinical Implications for Osteoporosis
- Scientists Study Bone Recovery in Smokers
- Institute for the Study of Aging Receives Generous Donation From Elan Pharmaceuticals to Create a New Alzheimer's Disease Research Program
- Study: Bone-Saving Drug Works for Decade
- Bear Study May Aid Osteoporosis Research
 |
 |
User Comments (0)
RSS Feeds